



Melanoma
World Society
MWS

Under the auspices
of the Melanoma
World Society

Cape Town, South Africa
March 1st-2nd, 2019

Update on Melanoma/ Skin Cancer 2019

**3rd International Educational
Symposium of the MWS**

Course Directors

Claus Garbe, Tuebingen, Germany

Axel Hauschild, Kiel, Germany

Dagmar Whitaker, Cape Town, South Africa



Final Program



MISSION 2

FINAL PROGRAM 3

CONGRESS FACULTY 8

GENERAL INFORMATION 10

CONTENT

The following missions will guide the activities of MWS:

Improve Medical Education

MWS will host the World Congress of Melanoma every four years, following the tradition since 1985. MWS will care for grants in order to make attendance of physicians from developing countries possible. MWS will organize the World Meeting of Melanoma/Skin Cancer Centers annually in between the World Congress of Melanoma. MWS will support educational meetings in countries with less experience in melanoma diagnosis and treatment.

Improve Guideline Development

MWS intends to unify diagnostic and therapeutic strategies in melanoma worldwide. MWS will establish a MELANOMA KNOWLEDGE DATABASE (MKD), which contains all relevant articles for evidence based medicine in melanoma, and additionally evidence tables of these articles. MKD will be accessible for all national guideline groups. MWS will organize international expert meetings in order to develop recommendations for diagnosis and treatment of melanoma in the rapidly changing landscape.

Improve Patient's Access to New Treatments

MWS intends to provide melanoma patients worldwide access to new and more efficacious treatments. MWS will address governments in order to achieve a more rapid reimbursement of new treatments. MWS will address pharmaceutical companies in order to achieve access to new treatment modalities in countries, where the high costs cannot be reimbursed.

Improve Clinical Research in Melanoma

MWS will coordinate clinical research activities in melanoma internationally. MWS will perform international clinical trials in indications, which are not investigated by the pharmaceutical industries. MWS will support international expert meetings in order to coordinate clinical research.

Friday, March 1st, 2019

08:00–09:00 Global incidence and mortality rates of skin cancer

Chairs: Jean Jacques Grob, Dagmar Whitaker

08:00–08:12 Non-melanoma skin cancer

Claus Garbe, Tuebingen, Germany

08:15–08:27 Melanoma

Jean Jacques Grob, Marseille, France

08:30–08:37 Update on epidemiology in South Africa

Caradee Wright,
Johannesburg, South Africa

08:40–09:00 Panel discussion: Falling rates in the foreseeable future?

Claus Garbe, Jean Jacques Grob,
Dagmar Whitaker

09:00–10:00 Dermoscopic diagnosis of skin cancer

Chairs: Gary Levy, Iris Zalaudek

09:00–09:27 Pigmented lesions

Gary Levy, Johannesburg, South Africa

09:30–09:57 Pink lesions

Iris Zalaudek, Trieste, Italy

10:00–10:30 Coffee Break

10:30–11:00 Key note lecture

Chair: Alberto Wainstein

New devices for skin cancer diagnosis

Axel Hauschild, Kiel, Germany

11:00–12:00 Controversy: Lymph node surgery improves survival

Chairs: Roland Kaufmann, Alberto Wainstein

11:00–11:17 Yes

Alex Landau, Cape Town, South Africa

11:20–11:37 No

Claus Garbe, Tuebingen, Germany

11:40–12:00 Panel discussion: The future of CLND

Alberto Wainstein, Roland Kaufmann,
Alex Landau

FINAL PROGRAM

12:00–13:00 Satellite Symposium Roche with lunch bags

13:00–13:30 Break

13:30–14:30 Controversy: Adjuvant treatment for BRAF mutated melanoma

Chair: **Axel Hauschild, Jean Jacques Grob**

13:30–13:42 PD-Antibodies first
Jean Jacques Grob, Marseille, France

13:45–13:57 Dabrafenib plus Trametinib first
Grant McArthur, Melbourne, Australia

14:00–14:12 Is there still a role for interferon treatment?
Sameera Dalvie, Cape Town, South Africa

14:15–14:30 Panel discussion: Which treatment first?
**Axel Hauschild, Grant McArthur,
Jean Jacques Grob**

14:30–15:30 Oncogene-driven treatment of advanced melanoma

Chairs: **Dirk Schadendorf, Willie Visser**

14:30–14:42 Molecular testing in melanoma:
update 2019
**Christopher Philipp Maske,
Johannesburg, South Africa**

14:45–14:57 Update on targeted therapies
Dirk Schadendorf, Essen, Germany

15:00–15:12 Management of adverse events
Willie Visser, Cape Town, South Africa

15:15–15:30 Panel discussion:
Perspectives of targeted therapy
**Christopher Philipp Maske, Willie Visser,
Dirk Schadendorf**

15:30–16:00 Coffee Break

16:00–17:00 Immunotherapy of advanced melanoma

Chairs: Jean Jacques Grob, Willie Visser

16:00–16:17 Mechanisms of immune checkpoint modulation

Christoffer Gebhardt, Hamburg, Germany

16:20–16:37 Update on clinical trials

Jean Jacques Grob, Marseille, France

16:40–16:57 Management of autoimmune events

Willie Visser, Cape Town, South Africa

17:00–17:30 Key note lecture

Chair: Dirk Schadendorf

Combinational approaches in metastatic melanoma: the future!?

Grant McArthur, Melbourne, Australia

17:30–18:30 Systemic treatment of advanced non-melanoma skin cancer

Chairs: Willie Visser, Christoffer Gebhardt

17:30–17:47 Basal cell carcinoma

Bianca Tod, Cape Town, South Africa

17:50–18:07 Merkel cell carcinoma

Christoffer Gebhardt, Hamburg, Germany

18:10–18:27 Squamous cell carcinoma

Axel Hauschild, Kiel, Germany

18:30 Get-together in the industrial exhibition

Saturday, March 2nd, 2019

08:00–09:00 Sunscreens protect against skin cancer!

Chairs: Jean Jacques Grob, Dagmar Whitaker

08:00–08:17 Yes

Jean Jacques Grob, Marseille, France

08:20–08:37 No

Claus Garbe, Tuebingen, Germany

08:40–09:00 Panel discussion: Primary prevention of skin cancer

Claus Garbe, Jean Jacques Grob,
Dagmar Whitaker

09:00–10:00 Interdisciplinary case discussions: Melanoma

Chair: Dirk Schadendorf

Case discussion panel

Roland Kaufmann, Dirk Schadendorf

09:00–09:12 Case one

Charles Thatcher,
Johannesburg, South Africa

09:15–09:27 Case two

Sameera Dalvie, Cape Town, South Africa

09:30–09:42 Case three

Johann De Wet, Cape Town, South Africa

09:45–09:5 Case four

Rupesh Misra, East London, South Africa

10:00–10:30 Coffee Break with guided Poster Viewing

**10:30–11:30 Interdisciplinary case discussion session:
Non melanoma skin cancer**

Chair: Willie Visser

Case discussion panel

Willie Visser, Christoffer Gebhardt, Iris Zalaudek

11:15–11:27 Case one
Willie Visser, Cape Town, South Africa

11:30–11:42 Case two
Christoffer Gebhardt, Hamburg, Germany

11:45–11:57 Case three
Iris Zalaudek, Trieste, Italy

12:00–12:12 Case four
Johann De Wet, Cape Town, South Africa

**11:30–12:30 Follow-up examinations: How often, how long,
which procedures?**

Chairs: Claus Garbe, Dagmar Whitaker

12:15–12:27 Follow-up of melanoma
Claus Garbe, Tuebingen, Germany

12:30–12:42 Follow-up of non-melanoma skin cancer
Dagmar Whitaker,
Cape Town, South Africa

12:45–13:15 Panel discussion
Claus Garbe, Dirk Schadendorf,
Dagmar Whitaker

12:30–13:00 Lunch Break

**13:00–16:00 Dermoscopy Course
Case-based discussions on melanoma and
non-melanoma skin cancer**

Iris Zalaudek, Robert Weiss

16:00 End of conference

Congress Faculty

D

Sameera Dalvie, MD

College of Radiation Oncology
Groote Schuur Hospital
Main Rd, Observatory
Cape Town
South Africa

Johann De Wet, MD

Division of Dermatology, Department of
Medicine
Stellenbosch University
Tygerberg Hospital
Cape Town
South Africa

G

Claus Garbe, MD

Professor of Dermatology
Department of Dermatology
Eberhard Karls University
Liebermeister Str. 25
72076 Tuebingen
Germany

Christoffer Gebhardt, MD

Skin Cancer Center
University Hospital Hamburg-Eppendorf
Martinistr. 52
20246 Hamburg
Germany

Jean Jacques Grob, MD

Professor of Dermatology
Service de Dermatology and Cancer
Research
Hospital de la Timone
264 Rue St. Pierre
13005 Marseille
France

H

Axel Hauschild, MD

Professor of Dermatology
Department of Dermatology
University of Kiel
Rosalind-Franklin-Str. 7
24105 Kiel
Germany

K

Roland Kaufmann, MD

Professor of Dermatology, Director
Department of Dermatology
Clinical Center J. W. Goethe University
Theodor-Stern-Kai 7
60590 Frankfurt am Main
Germany

L

Alex Gil Landau, MD

Room 201 Fairfield Medical Suites
Wildernes Road
Claremont, Cape Town 7708
South Africa

Gary Levy, MD

Suite 1A Rochester Place
173 Rivonia Road
Johannesburg
South Africa

M

Christopher Philipp Maske, MD

Lancet Corner Building
Cnr Stanley Avenue & Napier Road
Richmond, 2092
Johannesburg
South Africa

Grant McArthur, MD

Professor of Medicine
Head Cancer Therapeutics Program
Head Skin and Melanoma Service
Divisions of Cancer Medicine and
Research
Peter MacCallum Cancer Centre
Locked Bag 1A'Beckett St
Melbourne 8006
Australia

Rupesh Misra, MD

University of Cape Town
East London
South Africa

S

Dirk Schadendorf, MD

Professor of Dermatology
Department of Dermatology
University Hospital Essen
Hufelandstr. 55
45147 Essen
Germany

T

Charles Thatcher, MD

Eighth Avenue, Parktown North
Johannesburg, Gauteng
South Africa

Bianca Tod, MD

Stellenbosch University
Tygerberg Academic Hospital
Cape Town
South Africa

V

Willie Visser, MD

Head of Dermatology
Division of Dermatology
Departement Geneeskunde Faculty
of Medicine and Health Sciences
Stellenbosch University
Posbus 241, Cape Town
South Africa

W

Alberto Wainstein, MD

Professor of Medicine
Medical Science Faculty
of Minas Gerais (CMMG)
Belo Horizonte
Brazil

Robert Weiss, MD

Private Practice in Johannesburg
37A Keyes Avenue, Rosebank,
Johannesburg 2196
South Africa

Dagmar Whitaker, MD

1 Wytham Ave, Kenilworth Cape Town
Western Cape
South Africa

Caradee Wright, MD

Associate Professor
University of Johannesburg
Johannesburg
South Africa

Z

Iris Zalaudek, MD

Head of the Dermatology Clinic
University of Trieste
Hospital Maggiore
Piazza dell' Ospedale 1
34125 Trieste
Italy

General Information

Exhibition Opening Hours

Friday, March 1st: 07:30–19:00

Saturday, March 2nd: 07:30–16:30

Insurance

The Organizer does not accept liability for individual medical, travel or personal insurance and participants are strongly advised to make their own arrangements in respect to health and travel insurance.

Language

The official language of the meeting is English. Simultaneous translation will not be provided.

Meeting Organization

MEDCONCEPT

MedConcept

Gesellschaft für medizinische Projekte mbH

Mr Christopher Huhn

Friedenstraße 58

15366 Neuenhagen b. Berlin, Germany

Phone: +49 (0)3342 42689-30

Fax: +49 (0)3342 42689-40

Email: christopher.huhn@medconcept.org or info@medconcept.org

www.medconcept.org

Meeting Venue

The Rotunda

69 Victoria St

Camps Bay, Cape Town, 8001

South Africa

Phone: +27 (0)21 430 4444

Email: res@thebay.co.za

The registration desk is situated at the entrance of the Rotunda.

Registration Desk Opening Hours

Thursday, February 28th: 16:00–18:00 (early check-in)

Friday, March 1st: 07:00–19:00

Saturday, March 2nd: 07:00–17:00

Registration Fees

	Early registration until Jan. 31 th	From Feb. 1 st until Feb. 22 nd	Late Fee
Full Delegates	Africa		
	3,000 Rand	3,500 Rand	4,000 Rand
	Rest of World		
	300 Euro	350 Euro	400 Euro

Cancellation Policy

Cancellations must be received in writing by January 25th, 2019. No refunds will be granted after that date. To cancel a registration, please send an Email to info@medconcept.org. A processing fee of 150 Rand for Africa and 30 Euro for the Rest of the World will be deducted from each cancelled registration.

Substitutions are possible and must be received in writing by February 15th, 2019. To substitute a registration please send an email including the name of the original registrant and the name of the person substituting to info@medconcept.org.

The participant acknowledges that he/she has no right to lodge damage claims against the organizers should the holding of the meeting be hindered or prevented by unexpected, political or economic events or generally by force, or should the non-appearance of speakers or other reasons need program changes. With registration, the participant accepts this proviso.

Sponsors

Gold



Roche

Silver



Bristol-Myers Squibb

Bristol-Myers Squibb

Bronze



MSD

MSD

Further Sponsors

Beiersdorf

Beiersdorf

BIODERMA
LABORATOIRE DERMATOLOGIQUE

BioDerma

BioNike

BioNike

FotoFinder®

Fotofinder

GALDERMA

Galderma

Genop
healthcare

Genop Healthcare

ISDIN

ISDIN

NOVARTIS

Novartis



Zelboraf[®] in patients with BRAF^{V600E} mutation - positive metastatic melanoma: ^{1,2}

- Produces a robust increase in progression-free survival compared to dacarbazine: 6,9 months vs 1,6 months (HR 0,39; $p < 0,0001$) ¹
- Zelboraf[®] is associated with a highly significant improvement in response rate vs dacarbazine (59 % vs 11 %) ¹
- Medium time to response with Zelboraf[®] is 1,4 months ¹
- A well-characterised, manageable safety profile ²

Efficacy. Evidence. Experience.

Zelboraf[™]
vemurafenib

References: 1. McArthur GA, Chapman PB *et al.* Safety and efficacy of vemurafenib in BRAFV600E and BRAFV600K mutation-positive melanoma (BRIM-3): extended follow-up of a phase 3, randomized, open-label study. *Lancet Oncol* 2014;15:323-32. 2. Larkin J, del Vecchio M *et al.* Vemurafenib in patients with BRAFV600 mutated metastatic melanoma: an open-label, multicenter, safety study. *Lancet Oncol* 2014;15:436-44.

S4 ZELBORAF[®], 47/32.16/0247. Vermurafenib 240 mg per film-coated tablet. **ZELBORAF[®]** is indicated as monotherapy for the treatment of adult patients with BRAF V600E mutation-positive unresectable or metastatic melanoma. For full prescribing information refer to the package insert approved by the Medicines Regulatory Authority. Roche Products (Pty) Ltd, PO Box 55922, Northlands, 2116. Tel: 011 502 5000 or Toll-free on REAL (Roche Ethical Assistance Line): 0800 21 21 25. www.roche.co.za. SA/ZELB/1609/0005(01)

